GRAIL vs Sectra Pathology
A hospital pathology service that wants a vendor-neutral viewer with third-party AI on one contract is Sectra's customer. IDS7 covers worklists, reporting and image review, and Sectra says it has integrated more than 50 pathology AI vendors through its Amplifier marketplace. The Digital Pathology Module has K193054 from March 2020 and K232208 from April 2024, the later one for FFPE primary diagnosis with the Leica Aperio GT 450 DX and a specified Dell display, in SVS and DICOM. Sectra says one viewer covers pathology, radiology and genomics images.
Galleri looks for methylation signals from more than 50 cancer types in a blood sample. It is meant for adults 50 and older, in addition to guideline-recommended screening, and GRAIL states that it does not detect a signal for every cancer.
These two sit with different buyers. A hospital signs the Sectra contract for its image workflow, and a clinician prescribes Galleri to a patient.
Pathology · Reviewed November 2, 2026
GRAIL
by GRAIL
Galleri blood test for multi-cancer early detection, sold as a CLIA lab test. Not FDA cleared or approved.
Sectra Pathology
by Sectra
Digital pathology image management (Sectra IDS7) with a marketplace for third-party AI apps. Sectra does not make the AI.
When to pick each one
GRAIL
- Looks for signals from over 50 cancer types
- Meant for adults 50 and older
Sectra Pathology
- Digital Pathology Module K232208, DICOM supported
- Third-party AI apps on one contract
- Vendor says pathology, radiology and genomics share one viewer
Score
Each row shows points earned of points available under the published rubric.
GRAIL
28of 100
Sectra Pathology
33of 100
| Dimension | GRAIL | Sectra Pathology | Difference |
|---|---|---|---|
| FDA clearance | 0 / 18 | 18 / 18 | -18 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 8.4 / 21 | 0 / 21 | +8.4 |
| RCT / meta-analysis / systematic review | 7.8 / 7.8 | 0 / 7.8 | +7.8 |
| Funding & adoption signal | 8.4 / 12 | 8.4 / 12 | 0 |
| Pricing transparency | 0 / 5 | 2.5 / 5 | -2.5 |
| Years in market | 0 / 6 | 0 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
GRAIL
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price verified. |
Sectra Pathology
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Contact form only. |
Evidence
GRAIL
FDA decisions
No FDA decision cited in our research as of November 2, 2026.
Peer-reviewed
1 PubMed record names GRAIL.
Sectra Pathology
FDA decisions
K232208 (opens in new tab)510(k)2024-04-16
Sectra Digital Pathology Module (Version 3.3)
K193054 (opens in new tab)510(k)2020-03-31
Sectra Digital Pathology Module
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | GRAIL | Sectra Pathology |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | n/a | n/a |
| HQ | US | SE |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.